Immunomodulation in Cancer Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 124

Special Issue Editor


E-Mail Website
Guest Editor
Departments of Medicine and Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
Interests: immuno-metabolism; adoptive cell therapy

Special Issue Information

Dear Colleagues,

Immune therapy has revolutionized the treatment of cancer.  Much of the impact has been achieved due to immune checkpoint inhibitor (ICI) antibodies targeting the Programmed Death 1 (PD1) axis.  It is now clear that, unfortunately, these anti-PD1 ICIs alone are not sufficient to achieve durable tumor control in most patients with cancer. Fortunately, tremendous progress has been made in developing novel approaches to manipulate the immune system to fight cancer.  These include cellular therapies, bi-specific T-cell engagers (BiTES) and therapies aimed at targeting immunometabolism, the microbiome or non-T cell populations of immune cells.  We are pleased to invite you to contribute to this Special Issue of Cancers entitled “Immunomodulation in Cancer Treatment”.  This Special Issue will focus on novel approaches to manipulating the immune response against cancer that demonstrate the potential to translate to improved clinical outcomes. For this Special Issue, original research articles and reviews are welcome.  Research areas may include (but are not limited to) the following:

  • Cell therapies utilizing tumor-infiltrating lymphocytes (TILs), T-cell receptor transgenic T-cells (TCR-T) or chimeric antigen receptor T-cells (CAR-T);
  • Bispecific antibodies or T-cell engagers;
  • Novel cytokine therapies;
  • Microbiome-targeted therapies;
  • Immuno-metabolic treatments;
  • Therapies targeting innate lymphoid cells (ILCs), macrophages or other innate immune cells.

We look forward to receiving your contributions.

Dr. Samuel D. Saibil
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adoptive cell therapy
  • TILs
  • TCT-T
  • BiTes
  • CAR-T
  • immuno-metabolism
  • immune therapy

Published Papers

This special issue is now open for submission.
Back to TopTop